Shari Mycek

Final overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.

In a first-of-its-kind study, data reveal that unnecessary antibiotic use may increase the risk of colon cancer—especially in people under age 50. Findings were presented at the 2021 World Congress on Gastrointestinal Cancer.

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials, according to a poster presented at the European Hematology Association 2021 Virtual Congress.

Results from a phase 2 trial of patients with HER2-positive breast comparing TCbH alone and TCbH with pyrotinib showed significant improvement when adding pyrotinib, according to data presented at ASCO.

Overall survival was maintained, and even improved, in patients with pretreated HER2-positive breast cancer receiving tucatinib plus trastuzumab and capecitabine versus placebo.

Pembrolizumab plus concurrent chemoradiation therapy continues to demonstrate promising antitumor activity in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.